-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NEO-212 in Astrocytoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NEO-212 in Astrocytoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NEO-212 in Astrocytoma Drug Details: NEO-212 is under development for the treatment of astrocytoma,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NEO-212 in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NEO-212 in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NEO-212 in Glioblastoma Multiforme (GBM) Drug Details: NEO-212 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NEO-212 in Metastatic Brain Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NEO-212 in Metastatic Brain Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NEO-212 in Metastatic Brain Tumor Drug Details: NEO-212 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NEO-201 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NEO-201 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NEO-201 in Non-Small Cell Lung Cancer Drug Details: NEO-201 (h16C3)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NEO-2734 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NEO-2734 in Solid Tumor Drug Details: NEO-2734 is under development for the treatment of solid...
-
Product Insights
Project Neo Wind Farm
Project Neo Wind Farm is an Onshore Wind project located in New South Wales, Australia. The project is owned and being developed by Infinite Green Energy Pty Ltd. The project is expected to come online in 2038. Empower your strategies with our Project Neo Wind Farm report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NEO-2734 in Castration-Resistant Prostate Cancer (CRPC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NEO-2734 in Castration-Resistant Prostate Cancer (CRPC) Drug Details: NEO-2734 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NEO-2734 in NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NEO-2734 in NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NEO-100 in Meningioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NEO-100 in Meningioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NEO-100 in MeningiomaDrug Details:NEO-100 is under development for the treatment of glioblastoma multiforme, and...